Last reviewed · How we verify
DWJ1252
DWJ1252 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
At a glance
| Generic name | DWJ1252 |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without publicly available information on DWJ1252's molecular target or mechanism, the precise biological pathway cannot be determined. Phase 3 status indicates the drug has progressed through early-stage testing, but detailed mechanistic data remains proprietary or unpublished.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PHASE3)
- Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2) (PHASE3)
- Clinical Trials to Compare Mosapride Bioavailability Between DWJ1252 and Mosapride Medicine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DWJ1252 CI brief — competitive landscape report
- DWJ1252 updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI